enGene Holdings Inc Common Stock
Yahoo Finance • 2 days ago
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H... Full story
Yahoo Finance • 20 days ago
EnGene Holdings Inc. Q3 Loss Increases, Misses Estimates
(RTTNews) - enGene Holdings Inc. (ENGN) announced Loss for its third quarter that increased from the same period last year and missed the Street estimates. The company's bottom line totaled -$28.99 million, or -$0.57 per share. This com... Full story
Yahoo Finance • 21 days ago
enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles
enGene Holdings Inc (NASDAQ:ENGN [https://www.chartmill.com/stock/quote/ENGN]) reported its third quarter 2025 financial results, posting a net loss per share that came in wider than analyst expectations. The clinical-stage biotechnology c... Full story
Yahoo Finance • 2 months ago
Video Processing Platform Markets: Video Encoding & Transcoding, Video Management,Video Ingest & Capture, Video Delivery & Distribution, Video Editing & Enhancement - Global Forecast to 2030
Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Video Processing Platform Market by Offering (Video Encoding & Transcoding, Video Management), Content Type (VOD, Short Form Video), Application (Video Ingest & Capture, Video Delivery & Dis... Full story
Yahoo Finance • 3 months ago
FDA grants RMAT designation to enGene's bladder cancer therapy
BOSTON/MONTREAL - The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to enGene Holdings Inc.’s (NASDAQ:ENGN) lead therapy for treating high-risk bladder cancer, the company announced... Full story
Yahoo Finance • 4 months ago
Engene stock maintains buy rating at H.C. Wainwright on LEGEND trial
H.C. Wainwright has reiterated a buy rating and $25.00 price target on Engene Holdings Inc. (NASDAQ:ENGN), citing progress in the company’s pivotal LEGEND trial for high-risk non-muscle invasive bladder cancer (NMIBC). Currently trading at... Full story
Yahoo Finance • 5 months ago
Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?
We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where enGene Holdings Inc. (NASDAQ:ENGN) stands against other best Canadian penny stocks to invest in now. We d... Full story
